Posted by Michael Wonder on 29 May 2024
Zanubrutinib in combination with obinutuzumab for the treatment of patients with relapsed or refractory B-cell follicular lymphoma after two or more treatments
28 May 2024 - NICE is unable to make a recommendation on the use of zanubrutinib (Brukinsa) in combination with obinutuzumab for the treatment of adults with relapsed or refractory B-cell follicular lymphoma after two or more treatments because BeiGene requested a delay to the evidence submission.
NICE will review this decision if BeiGene decides to make a submission.
